ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace

ANI Pharmaceuticals reported record Q2 2026 revenue of $266 million and adjusted EBITDA of $71.6 million, while reiterating full-year revenue guidance of $1.08 billion-$1.14 billion and EBITDA guidance of $285 million-$300 million. Cortrophin sales rose 43% year over year to $117.1 million, though its 2026 guidance was previously reduced to $520 million-$540 million from $540 million-$575 million; management expects the expanded gout sales force to support second-half growth. ANI generated $100 million of first-half free cash flow, ended June with $360 million in cash and roughly 1.0x net leverage, and has a $100 million repurchase authorization to complement rare-disease M&A ambitions.

Analysis

The valuation disconnect is less about whether ANI can grow and more about whether the market will capitalize Cortrophin as a durable rare-disease franchise rather than a single-asset, reimbursement-sensitive specialty product. The key underwriting issue is the required second-half exit rate: achieving the midpoint implies a materially higher quarterly run-rate than the first half, making prescription-to-paid conversion, prior-authorization friction, and gross-to-net trends more important than early new-patient metrics. The enlarged field force also creates near-term operating deleverage risk; revenue can lead reported EBITDA only if salesforce productivity scales without incremental patient-support and access costs.

The gout expansion could create meaningful 2027 operating leverage if it adds patients without cannibalizing specialist-originated demand, but it also moves ANI into a more payer-controlled primary-care channel where utilization management can be tighter. Management's long-dated IP framing should not be equated with revenue certainty: formulary exclusion, payer step edits, clinical-practice resistance, and a revived competitive commercialization effort could impair realized durability well before patent expiration. The more consequential upside catalyst is a disciplined bolt-on acquisition using its underlevered balance sheet; the corresponding tail risk is that a larger deal re-rates ANI from cash-generative specialty pharma to a levered serial acquirer.

Key Decisions for Investors

• Initiate a starter long ANIP only after the next earnings release confirms Cortrophin net sales and full-year guidance, then add on evidence that the implied second-half run-rate is being met. Target a 12-month rerating toward a rare-disease/specialty-pharma EBITDA multiple; cut or reassess if Cortrophin guidance is reduced again or EBITDA margin fails to expand despite revenue growth.
• Use a 1-3 month event watch around third-quarter results rather than chasing conference commentary: require disclosure of paid-start persistence, refill behavior, gross-to-net, and salesforce productivity by territory. Absence of these metrics, or a widening gap between new cases and recognized revenue, is a signal to avoid the long.
• Treat the Q4 ILUVIEN clinical-data presentation as a modest upside optionality catalyst, not a core valuation driver. Add exposure only if the detailed safety/efficacy profile can plausibly improve retina-specialist adoption; negative safety detail would weaken cross-selling economics and challenge the rare-disease platform narrative.
• Monitor capital deployment closely: a cash-funded, commercial-stage rare-disease bolt-on that leverages existing nephrology, rheumatology, neurology, ophthalmology, or patient-services infrastructure is constructive; a transaction that pushes leverage materially toward management's ceiling without clearly accretive cash flow is a thesis-break risk and warrants reducing exposure.